ASHINGTON — The Food and Drug Administration will relax its review of some genetic tests that examine millions of different variants at the same time, the agency announced Thursday.

So far, the FDA has not approved any of these broad “next-generation sequencing” tests, but as their cost drops, the agency believes they have more potential to help patients.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.